Femasys Inc. (FEMY)
1.74
0.05 (2.96%)
At close: Feb 20, 2025, 3:59 PM
1.77
1.73%
After-hours: Feb 20, 2025, 05:50 PM EST
undefined% (undefined)
| Bid | 1.77 |
| Market Cap | 39.84M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.81 |
| PE Ratio (ttm) | -2.15 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.8 |
| Volume | 587,952 |
| Avg. Volume (20D) | 265,611 |
| Open | 1.66 |
| Previous Close | 1.69 |
| Day's Range | 1.57 - 1.79 |
| 52-Week Range | 0.86 - 2.40 |
| Beta | undefined |
About FEMY
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United Sta...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jun 18, 2021
Employees 32
Stock Exchange NASDAQ
Ticker Symbol FEMY
Website https://www.femasys.com
Analyst Forecast
According to 3 analyst ratings, the average rating for FEMY stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 474.71% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Femasys Inc. is scheduled to release its earnings on Mar 27, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+7.48%
Femasys shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago
+10.48%
Femasys shares are trading higher after the company announced CE Mark and Health Canada approved its FemVue MINI fallopian tube assessment solution
